Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2018	May 01, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Registrant Name	AVENUE THERAPEUTICS, INC.
Entity Central Index Key	0001644963
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	ATXI
Entity Common Stock, Shares Outstanding		10,553,045

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 14,963	$ 11,782
Short-term investments	0	10,000
Prepaid expenses and other current assets	310	388
Total Assets	15,273	22,170
Current Liabilities:
Accounts payable and accrued expenses	5,753	2,737
Accounts payable and accrued expenses - related party	167	53
Total current liabilities	5,920	2,790
Total Liabilities	5,920	2,790
Commitments and Contingencies
Stockholders' Equity
Common Stock ($0.0001 par value), 50,000,000 shares authorized Common shares; 10,552,045 and 10,265,083 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	1	1
Common stock issuable, 0 and 273,837 shares as of March 31, 2018 and December 31, 2017, respectively	0	1,103
Additional paid-in capital	40,390	38,937
Accumulated deficit	(31,038)	(20,661)
Total Stockholders' Equity	9,353	19,380
Total Liabilities and Stockholders' Equity	15,273	22,170
Series A Preferred Stock [Member]
Stockholders' Equity
Preferred Stock ($0.0001 par value), 2,000,000 shares authorized Class A Preferred Stock, 250,000 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	$ 0	$ 0

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Shares, Issued	10,552,045	10,265,083
Common Stock, Shares, Outstanding	10,552,045	10,265,083
Common Stock Shares issuable	0	273,837
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued	250,000	250,000
Preferred Stock, Shares Outstanding	250,000	250,000

CONDENSED STATEMENT OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
CONDENSED STATEMENT OF OPERATIONS - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Operating expenses:
Research and development	$ 9,439	$ 133
General and administration	986	371
Loss from operations	(10,425)	(504)
Interest income	(48)	0
Interest expense	0	95
Interest expense - related party	0	61
Change in fair value of convertible notes payable	0	4
Change in fair value of warrant liabilities	0	(3)
Net Loss	$ (10,377)	$ (661)
Net loss per common share outstanding, basic and diluted	$ (1.03)	$ (0.22)
Weighted average number of common shares outstanding, basic and diluted	10,099,331	3,022,846

CONDENSED STATEMENT OF STOCKHOLDERS’ EQUITY - 3 months ended Mar. 31, 2018 - USD ($) $ in Thousands	Total	Class A Preferred [Member]	Common Stock [Member]	Common Stock issuable [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]
Balance at Dec. 31, 2017	$ 19,380	$ 0	$ 1	$ 1,103	$ 38,937	$ (20,661)
Balance (Shares) at Dec. 31, 2017		250,000	10,265,083	273,837
Issuance of common shares - Founders Agreement	0	$ 0	$ 0	$ (1,103)	1,103	0
Issuance of common shares - Founders Agreement (in shares)		0	273,837	(273,837)
Exercise of warrants under the NSC Note	0	$ 0	$ 0	$ 0	0	0
Exercise of warrants under the NSC Note (in shares)		0	13,125	0
Share based compensation	350	$ 0	$ 0	$ 0	350	0
Share based compensation (in shares)		0	0	0
Net loss	(10,377)	$ 0	$ 0	$ 0	0	(10,377)
Balance at Mar. 31, 2018	$ 9,353	$ 0	$ 1	$ 0	$ 40,390	$ (31,038)
Balance (Shares) at Mar. 31, 2018		250,000	10,552,045	0

CONDENSED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
CONDENSED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (10,377)	$ (661)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation	350	5
Change in fair value of convertible notes payable	0	4
Change in fair value of warrant liabilities	0	(3)
Debt discount amortization	0	33
Changes in operating assets and liabilities:
Prepaid expenses	78	0
Accounts payable and accrued expenses	3,016	362
Accounts payable and accrued expenses - related party	114	220
Interest payable	0	(52)
Accrued interest - related party	0	58
Net cash used in operating activities	(6,819)	(34)
Cash flows from investing activities:
Maturity of Short-term investments (certificates of deposits)	10,000	0
Net cash provided by investing activities	10,000	0
Cash flows from financing activities:
Deferred financing costs	0	(234)
Proceeds from notes payable - related party	0	71
Net cash used in financing activities	0	(163)
Net change in cash	3,181	(197)
Cash and cash equivalents, beginning of period	11,782	197
Cash and cash equivalents, end of period	14,963	0
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 0	$ 115

Organization, Plan of Business Operations

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 - Organization, Plan of Business Operations

Avenue Therapeutics, Inc. (the “Company” or “Avenue”) was incorporated in Delaware on February 9, 2015, as a wholly owned subsidiary of Fortress Biotech, Inc. (“Fortress”), to develop and market pharmaceutical products for the acute care setting in the United States. The Company will focus on developing its product candidate, an intravenous (“IV”) formulation of tramadol HCI (“IV Tramadol”), for moderate to moderately severe post-operative pain.

Liquidity and Capital Resources

The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future as it executes on its product development plan and may never become profitable. As of March 31, 2018, the Company had an accumulated deficit of $31.0 million.

The Company’s development plan anticipates that its cash and cash equivalents at March 31, 2018 will provide sufficient liquidity for the period through May 3, 2019. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements. If such funding is not available or not available on terms acceptable to the Company, the current development plan will be curtailed.

Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 — Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited interim condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2017, which were included in the Company’s Form 10-K, and filed with the U.S. Securities and Exchange Commission (“SEC”) on March 1, 2018. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

The unaudited interim condensed financial statements may not be indicative of future performance and may not reflect what the results of operations, financial position, and cash flows would have been had Avenue operated as an independent entity. Certain estimates, including allocations from Fortress, have been made to provide financial statements for stand-alone reporting purposes. Inter-company transactions between Fortress and Avenue are classified as Accounts Payable and Accrued Expenses - Related Party in the unaudited interim condensed financial statements. The Company believes that the assumptions underlying the unaudited interim condensed financial statements are reasonable.

The Company has no subsidiaries.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Annual Stock Dividend

In September 2016, the Company issued 250,000 Class A preferred shares to Fortress. The Class A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (“The Annual Stock Dividend”).

The Company recorded the Annual Stock Dividend due to Fortress as contingent consideration. Contingent consideration is recorded when probable and reasonably estimable. The Company’s future share prices cannot be estimated due to the nature of its assets and the Company’s stage of development. Due to these uncertainties, the Company concluded that it could not reasonably estimate the contingent consideration until shares were actually issued on February 17, 2018 and February 17, 2017. Because the issuance of shares on February 17, 2018 and 2017 occurred prior to the issuance of the December 31, 2017 and 2016 financial statements, respectively, the Company recorded approximately $1.1 million and $49,000 in research and development - licenses acquired for the years ended December 31, 2017 and 2016, respectively.

Net loss per Share

Loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding, excluding unvested restricted stock and stock options, during the period. Since dividends are declared paid and set aside among the holders of shares of common stock and Class A common stock pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required.

The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:

	For the Three Months Ended
	March 31,		March 31,
	2018		2017
Restricted stock units/awards		714,999		274,999
Preferred shares		250,000		250,000
Options		20,000		-
Total potential dilutive effect		984,999		524,999

Recently Adopted Accounting Standards

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business (“ASU 2017-01”). The amendments in this ASU clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 in the first quarter of 2018 and its adoption did not have a material impact on the Company’s unaudited interim condensed financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, (“ASU 2017-09”) which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company early adopted ASU 2017-09 in the first quarter of 2018 and its adoption did not have a material impact on the Company’s unaudited interim condensed financial statements.

Allocation

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 3 — Allocation

The expense allocations to Avenue, which represent Lucy Lu’s executive compensation, have been paid by Fortress and allocated by the Company between Avenue and Fortress based on time spent on Avenue projects versus time spent on Fortress projects. The allocations were based on assumptions that management believes are reasonable; however, these allocations are not necessarily indicative of the costs and expenses that would have resulted if Avenue had been operating as a stand-alone entity. Since Lucy Lu became a full-time employee for Avenue in June 2017, the allocations ceased as her time spent was 100% devoted to Avenue. For the three months ended March 31, 2018 and 2017, the allocated expenses related to Lucy Lu were approximately $0 and $0.1 million, respectively, and were recorded 50% to research and development and 50% to general and administration expenses.

Related Party Agreements

3 Months Ended

Mar. 31, 2018

Note 4 — Related Party Agreements

Management Services Agreement with Fortress

Effective as of February 17, 2015, Fortress entered into a Management Services Agreement (the “MSA”) with Avenue to provide advisory and consulting services to Avenue for a period of five (5) years. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of Avenue’s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of Avenue with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). Avenue is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, Avenue is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of Avenue’s actions or inactions based upon their advice. Fortress and its affiliates, including all members of Avenue’s Board of Directors, have been contractually exempt from fiduciary duties to Avenue relating to corporate opportunities. In consideration for the Services, Avenue will pay Fortress an annual consulting fee of $0.5 million (the “Annual Consulting Fee”), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar year in which Avenue has net assets in excess of $100.0 million at the beginning of the calendar year. For the three months ended March 31, 2018 and 2017, the Company had expenses related to the MSA of approximately $0.1 million, respectively.

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 5— Accounts Payable and Accrued Expenses

Accounts payable, accrued expenses and other liabilities consisted of the following (in thousands):

	As of March 31,		As of December 31,
	2018		2017
Accounts payable	$	3,909	$	1,545
Accrued employee compensation		73		215
Accrued contracted services and other		1,771		977
Accounts payable and accrued expenses	$	5,753	$	2,737

Stockholders’ Equity

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 6 — Stockholders’ Equity

Awards to Fortress

Pursuant to the Company’s Second Amended and Restated Certificate of Incorporation for the annual stock dividend that was due on February 17, 2018, the Company issued 273,837 shares of common stock to Fortress, which equaled to 2.5% of the fully diluted outstanding equity of Avenue at the time of issuance for the annual stock dividend.

Equity Incentive Plan

The Company has in effect the 2015 Incentive Plan (“2015 Incentive Plan”). The 2015 Incentive Plan was adopted in January 2015 by our stockholders. Under the 2015 Incentive Plan, the compensation committee of the Company’s board of directors is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan authorizes grants to issue up to 2,000,000 shares of authorized but unissued common stock and expires 10 years from adoption and limits the term of each option to no more than 10 years from the date of grant.

Restricted Stock Units and Restricted Stock Awards

The following table summarizes restricted stock unit and award activity for the three months ended March 31, 2018:

	Number of Units and Awards		Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2017		714,999	$	5.00
Granted		-	$	-
Vested		-	$	-
Unvested balance at March 31, 2018		714,999	$	5.00

For the three months ended March 31, 2018 and 2017, stock-based compensation expenses associated with the amortization of restricted stock units and restricted stock awards for employees and non-employees were approximately $0.4 million and $5,000 respectively.

At March 31, 2018, the Company had unrecognized stock-based compensation expense related to restricted stock units and restricted stock awards of $2.5 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.3 years.

Stock Options

The following table summarizes stock option award activity for the three months ended March 31, 2018:

	Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding, December 31, 2017		20,000	$	6.29		4.63
Granted		-		-		-
Outstanding, March 31, 2018		20,000	$	6.29		4.38

Stock Warrants

The following table summarizes the warrant activity for the three months ended March 31, 2018:

	Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2017		123,413	$	0.0828	$	438
Exercised		(13,125)	$	0.0001
Outstanding, March 31, 2018		110,288	$	0.0929	$	487

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These unaudited interim condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

Therefore, these unaudited interim condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended December 31, 2017, which were included in the Company’s Form 10-K, and filed with the U.S. Securities and Exchange Commission (“SEC”) on March 1, 2018. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

The unaudited interim condensed financial statements may not be indicative of future performance and may not reflect what the results of operations, financial position, and cash flows would have been had Avenue operated as an independent entity. Certain estimates, including allocations from Fortress, have been made to provide financial statements for stand-alone reporting purposes. Inter-company transactions between Fortress and Avenue are classified as Accounts Payable and Accrued Expenses - Related Party in the unaudited interim condensed financial statements. The Company believes that the assumptions underlying the unaudited interim condensed financial statements are reasonable.

The Company has no subsidiaries.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Stockholders' Equity, Policy [Policy Text Block]

Annual Stock Dividend

In September 2016, the Company issued 250,000 Class A preferred shares to Fortress. The Class A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (“The Annual Stock Dividend”).

The Company recorded the Annual Stock Dividend due to Fortress as contingent consideration. Contingent consideration is recorded when probable and reasonably estimable. The Company’s future share prices cannot be estimated due to the nature of its assets and the Company’s stage of development. Due to these uncertainties, the Company concluded that it could not reasonably estimate the contingent consideration until shares were actually issued on February 17, 2018 and February 17, 2017. Because the issuance of shares on February 17, 2018 and 2017 occurred prior to the issuance of the December 31, 2017 and 2016 financial statements, respectively, the Company recorded approximately $1.1 million and $49,000 in research and development - licenses acquired for the years ended December 31, 2017 and 2016, respectively.

Earnings Per Share, Policy [Policy Text Block]

Net loss per Share

Loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding, excluding unvested restricted stock and stock options, during the period. Since dividends are declared paid and set aside among the holders of shares of common stock and Class A common stock pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required.

The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:

	For the Three Months Ended
	March 31,		March 31,
	2018		2017
Restricted stock units/awards		714,999		274,999
Preferred shares		250,000		250,000
Options		20,000		-
Total potential dilutive effect		984,999		524,999

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Standards

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business (“ASU 2017-01”). The amendments in this ASU clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 in the first quarter of 2018 and its adoption did not have a material impact on the Company’s unaudited interim condensed financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, (“ASU 2017-09”) which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company early adopted ASU 2017-09 in the first quarter of 2018 and its adoption did not have a material impact on the Company’s unaudited interim condensed financial statements.

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]

The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:

	For the Three Months Ended
	March 31,		March 31,
	2018		2017
Restricted stock units/awards		714,999		274,999
Preferred shares		250,000		250,000
Options		20,000		-
Total potential dilutive effect		984,999		524,999

Accounts Payable and Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

Accounts payable, accrued expenses and other liabilities consisted of the following (in thousands):

	As of March 31,		As of December 31,
	2018		2017
Accounts payable	$	3,909	$	1,545
Accrued employee compensation		73		215
Accrued contracted services and other		1,771		977
Accounts payable and accrued expenses	$	5,753	$	2,737

Stockholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]

The following table summarizes restricted stock unit and award activity for the three months ended March 31, 2018:

	Number of Units and Awards		Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2017		714,999	$	5.00
Granted		-	$	-
Vested		-	$	-
Unvested balance at March 31, 2018		714,999	$	5.00

Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option award activity for the three months ended March 31, 2018:

	Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding, December 31, 2017		20,000	$	6.29		4.63
Granted		-		-		-
Outstanding, March 31, 2018		20,000	$	6.29		4.38

Share-based Compensation, Activity [Table Text Block]

The following table summarizes the warrant activity for the three months ended March 31, 2018:

	Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2017		123,413	$	0.0828	$	438
Exercised		(13,125)	$	0.0001
Outstanding, March 31, 2018		110,288	$	0.0929	$	487

Organization, Plan of Business Operations (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Retained Earnings (Accumulated Deficit)	$ (31,038)	$ (20,661)

Significant Accounting Policies (Details) - shares	3 Months Ended
Significant Accounting Policies (Details) - shares	Mar. 31, 2018	Mar. 31, 2017
Total potential dilutive effect shares outstanding	984,999	524,999
Restricted stock units/awards
Total potential dilutive effect shares outstanding	714,999	274,999
Preferred shares
Total potential dilutive effect shares outstanding	250,000	250,000
Options
Total potential dilutive effect shares outstanding	20,000	0

Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Stock Issued During Period, Shares, New Issues	250,000
Preferred Stock, Dividend Rate, Percentage	2.50%
Research and Development in Process		$ 1,100,000	$ 49,000

Allocation (Details Textual) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
Allocation (Details Textual) - USD ($) $ in Millions	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017
Allocated Share-based Compensation Expense		$ 0.0	$ 0.1
Share Based Compensation Allocation Percentage	100.00%
Research and Development Expense [Member]
Share Based Compensation Allocation Percentage		50.00%
General and Administrative Expense [Member]
Share Based Compensation Allocation Percentage		50.00%

Related Party Agreements (Details Textual) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Feb. 17, 2015	Mar. 31, 2018	Mar. 31, 2017
Service Agreement Expenses		$ 0.1	$ 0.1
Asset Management Income [Member]
Annual Consulting Fee	$ 0.5
Increase In Annual Consulting Fee	1.0
Excess In Net Assets Value	$ 100.0

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts payable	$ 3,909	$ 1,545
Accrued employee compensation	73	215
Accrued contracted services and other	1,771	977
Accounts payable and accrued expenses	$ 5,753	$ 2,737

Stockholders’ Equity (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2018 $ / shares shares
Number of Units, Unvested Beginning Balance \| shares	714,999
Number of Units, Granted \| shares	0
Number of Units, Vested \| shares	0
Number of Units, Unvested Ending Balance \| shares	714,999
Weighted Average Grant Date Fair Value, Unvested Beginning Balance \| $ / shares	$ 5.00
Weighted Average Grant Date Fair Value, Granted \| $ / shares	0
Weighted Average Grant Date Fair Value, Vested \| $ / shares	0
Weighted Average Grant Date Fair Value, Unvested Ending Balance \| $ / shares	$ 5.00

Stockholders’ Equity (Details1) - $ / shares	3 Months Ended	12 Months Ended
Stockholders’ Equity (Details1) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Stock Options, Outstanding, Begining	20,000
Stock Options, Granted	0
Stock Options, Outstanding, Ending	20,000	20,000
Weighted Average Exercise Price, Outstanding, Begining	$ 6.29
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Outstanding, Ending	$ 6.29	$ 6.29
Weighted Average Remaining Contractual Life (in years)	4 years 4 months 17 days	4 years 7 months 17 days

Stockholders’ Equity (Details 2) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Number of Units, Unvested Beginning Balance	123,413
Warrants, Exercised	(13,125)
Number of Units, Unvested Ending Balance	110,288
Weighted Average Exercise Price, Outstanding	$ 0.0828
Weighted Average Exercise Price, Exercised	0.0001
Weighted Average Exercise Price, Outstanding	$ 0.0929
Aggregate Intrinsic Value	$ 487	$ 438

Stockholders’ Equity (Deficit) (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 17, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Share-based Compensation		$ 350,000	$ 5,000
2015 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms				10 years
Fortress Biotech, Inc [Member]
Stock Issuance Common Stock Issuable During Period, Shares	273,837
Percentage of Diluted outstanding Equity	2.50%
Restricted Stock [Member]
Share-based Compensation		$ 400,000	$ 5,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options		$ 2,500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 3 months 18 days

Stockholders’ Equity (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2018 $ / shares shares
Number of Units, Unvested Beginning Balance \| shares	714,999
Number of Units, Granted \| shares	0
Number of Units, Vested \| shares	0
Number of Units, Unvested Ending Balance \| shares	714,999
Weighted Average Grant Date Fair Value, Unvested Beginning Balance \| $ / shares	$ 5.00
Weighted Average Grant Date Fair Value, Granted \| $ / shares	0
Weighted Average Grant Date Fair Value, Vested \| $ / shares	0
Weighted Average Grant Date Fair Value, Unvested Ending Balance \| $ / shares	$ 5.00